FI931393A - Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus - Google Patents

Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus Download PDF

Info

Publication number
FI931393A
FI931393A FI931393A FI931393A FI931393A FI 931393 A FI931393 A FI 931393A FI 931393 A FI931393 A FI 931393A FI 931393 A FI931393 A FI 931393A FI 931393 A FI931393 A FI 931393A
Authority
FI
Finland
Prior art keywords
vaccinering
neutraliserande
motkroppar
inuktion
immunbristvirus
Prior art date
Application number
FI931393A
Other languages
English (en)
Other versions
FI931393A0 (fi
Inventor
Anders Vahlne
Bo Svennerholm
Lars Rymo
Stig Jeansson
Peter Horal
Original Assignee
Syntello Vaccine Dev Kb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntello Vaccine Dev Kb filed Critical Syntello Vaccine Dev Kb
Publication of FI931393A0 publication Critical patent/FI931393A0/fi
Publication of FI931393A publication Critical patent/FI931393A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI931393A 1990-09-27 1993-03-26 Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus FI931393A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58942290A 1990-09-27 1990-09-27
PCT/SE1991/000641 WO1992005800A1 (en) 1990-09-27 1991-09-25 Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus

Publications (2)

Publication Number Publication Date
FI931393A0 FI931393A0 (fi) 1993-03-26
FI931393A true FI931393A (fi) 1993-03-26

Family

ID=24357953

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931393A FI931393A (fi) 1990-09-27 1993-03-26 Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus

Country Status (13)

Country Link
US (1) US5589175A (fi)
EP (1) EP0550599B1 (fi)
JP (1) JPH06501260A (fi)
AT (1) ATE238065T1 (fi)
AU (1) AU650911B2 (fi)
CA (1) CA2091263C (fi)
DE (1) DE69133242T2 (fi)
ES (1) ES2194836T3 (fi)
FI (1) FI931393A (fi)
HU (1) HU9300877D0 (fi)
MC (1) MC2308A1 (fi)
OA (1) OA09802A (fi)
WO (1) WO1992005800A1 (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939074A (en) * 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
WO1992021377A1 (en) * 1991-06-03 1992-12-10 Syntello Inc. Peptides for use in induction of t cell activation against hiv-1
ES2257733T3 (es) * 1991-08-29 2006-08-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Antigenos peptidicos multideterminantes que estimulan la respuesta de los linfocitos auxiliares al hiv en una amplia gama de humanos.
IT1254360B (it) * 1992-05-11 1995-09-14 San Romanello Centro Fond Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
DE4228787A1 (de) * 1992-08-29 1994-03-03 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Neue HIV-1-Virusisolate eines Subtyps, Vakzine gegen HIV-1-Virusinfektionen dieses Subtyps und Verfahren zu ihrer Herstellung, Verwendung der HIV-1-Virusisolate
JPH09500096A (ja) * 1993-04-16 1997-01-07 シンテロ ヴァクシン デベロップメント アクチ ボラゲット ヒト免疫不全ウイルスに対する予防接種および中和抗体誘発に用いられるペプチド
FR2707169B1 (fr) * 1993-06-04 1995-09-01 Pasteur Institut Antigène cellulaire CD26 impliqué dans l'infection par un rétrovirus hiv. nouveaux inhibiteurs de l'infection par HIV. * (Dipeptidyl-peptidase IV).
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
AU2991197A (en) * 1996-04-15 1997-11-07 University Of North Carolina At Chapel Hill, The Antigenic sequences of a sperm protein and immunocontraceptive methods
WO1999024465A1 (en) * 1997-11-10 1999-05-20 Dana-Farber Cancer Institute Stabilized primate lentivirus envelope glycoproteins
EP2476437B1 (en) 2006-08-11 2018-11-28 Life Sciences Research Partners VZW Immunogenic peptides and their use in immune disorders
AU2009214039B2 (en) 2008-02-14 2013-09-19 Katholieke Universiteit Leuven Immunogenic control of tumours and tumour cells
EP2244733B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
ES2924027T3 (es) 2010-11-25 2022-10-04 Imcyse Sa Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
WO2017050966A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
RU2018136760A (ru) 2016-04-19 2020-05-19 Имсис Са НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387914B1 (en) * 1984-10-18 1993-08-04 Institut Pasteur Envelope antigens of the human immuno-deficiency virus, and their applications
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
WO1989005820A1 (en) * 1987-12-21 1989-06-29 Arch Development Corporation Hiv-related antigens and antibodies
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
AU3557889A (en) * 1988-04-20 1989-11-24 Trustees Of The University Of Pennsylvania, The Protective peptides derived from human immunodeficiency virus-1 gp160
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
JPH05506221A (ja) * 1990-04-03 1993-09-16 ジェネンテク，インコーポレイテッド Ｈｉｖエンベロープポリペプチド
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
WO1992021377A1 (en) * 1991-06-03 1992-12-10 Syntello Inc. Peptides for use in induction of t cell activation against hiv-1

Also Published As

Publication number Publication date
FI931393A0 (fi) 1993-03-26
DE69133242D1 (de) 2003-05-28
OA09802A (en) 1994-04-15
US5589175A (en) 1996-12-31
JPH06501260A (ja) 1994-02-10
CA2091263A1 (en) 1992-03-28
DE69133242T2 (de) 2004-02-19
MC2308A1 (fr) 1993-09-27
AU8643591A (en) 1992-04-28
EP0550599B1 (en) 2003-04-23
CA2091263C (en) 2003-05-06
AU650911B2 (en) 1994-07-07
ATE238065T1 (de) 2003-05-15
HU9300877D0 (en) 1993-06-28
EP0550599A1 (en) 1993-07-14
WO1992005800A1 (en) 1992-04-16
ES2194836T3 (es) 2003-12-01

Similar Documents

Publication Publication Date Title
FI931393A (fi) Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus
FI941199A0 (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DK0891982T3 (da) HIV-peptider
ES2013328A6 (es) Un metodo para detectar anticuerpos contra antigenos hiv-1.
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
AU5055593A (en) Antibodies specific for HIV
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
WO1991004273A3 (en) Novel peptides associated with the cd4 binding region of gp120 and their methods of use
AU3045497A (en) Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)
TR199801722T2 (xx) Peptit imm�nojenler.
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
CA2004478A1 (en) Monoclonal antibodies to feline-t-lymphotropic lentivirus
DE69332911T2 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
ATE87368T1 (de) Monoklonale antikoerper gegen nicht reduzierte, nicht enzymatisch glykolysierte proteine.
DE3584035D1 (de) Nachweis von menschlichem cytomegalovirus-spezifischem igm.
DE69330352T2 (de) Mittel und methoden zur verbesserung der keratinocytenadhäsion an der haut
ATE119203T1 (de) Monoklonale antikörper von mäusen gegen das gp41 protein von menschlichem immunmangelsyndrom- virus.
EP1104310A4 (en) EXPRESSION AND CHARACTERIZATION OF HIV-1 ENVELOPE PROTEIN ASSOCIATED WITH LARGELY REACTIVE NEUTRALIZATION ANTIBODY RESPONSE
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
RU94046321A (ru) Моноклональные муриновые антиидиотипические антитела, способ их получения и их применение, способы иммунизации и фармацевтический состав на их основе
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека

Legal Events

Date Code Title Description
FD Application lapsed